Can I answer the last one?
Basically, our objection is to the process. We have never, and will never, advocate for a specific drug. We have never asked CDR to re-examine drugs they've made a recommendation on, but over the last year and a half we have used the one drug that is recommended in our clinical practice guidelines to have some of the discussions around surrogate markers and all these other issues. We disagree with the process of CDR. Their recommendations are their recommendations.
On the process around the reviewers, right now the common drug review contracts reviewers to go through the literature and the clinical trials and draw up a summary of what the science says. Those people are confidential. That's fair enough. That's good. But you can never find out who they are, and you can never have the confidence that they're asking the right people to undertake these contracts.
We're suggesting that organizations like ours could be invited on an annual basis to give them a list of qualified experts on diabetes or endocrinology or even meta-analysis. It goes into a pool. They continue doing it the way they do currently, which is to look for the best-qualified person for the drug they're going to be examining. They contract that person. It doesn't have to be made public at that time; they just continue doing what they're doing. After they've made their recommendation public, a year later, without tying the individual to the study, they publish the names of those people they consulted over the last year. Then we can say they used them. It would give us a better sense of confidence that they're using the right people.